503 results on '"Wilding, John P H"'
Search Results
2. Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T
3. Risk of diabetic retinopathy and diabetic macular oedema with sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database
4. SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
5. Definition and diagnostic criteria of clinical obesity
6. Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes
7. Etiopathogenesis of Obesity
8. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
9. The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes‐related and cancer outcomes.
10. The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
11. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
12. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
13. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
14. #2496 Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial
15. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
16. Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data
17. Should obesity be recognised as a disease?
18. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
19. The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review
20. Obesity and Obstructive Sleep Apnea Syndrome
21. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
22. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
23. Etiopathogenesis of Obesity
24. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
25. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials
26. Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review
27. Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes
28. Natriuretic Peptides, Body Mass Index and Heart Failure Risk: Pooled Analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61
29. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
30. Metabolically healthy obesity: time for a change of heart?
31. The double burden of malnutrition in individuals: Identifying key challenges and re‐thinking research focus.
32. Patients’ Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography
33. Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes
34. No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled, cross‐over trial (ENERGIZE)
35. Corneal Confocal Microscopy Predicts Cardiovascular and Cerebrovascular Events and Demonstrates Greater Peripheral Neuropathy in Patients with Type 1 Diabetes and Foot Ulcers
36. Management of obesity
37. Regulation of energy balance — towards rational drug design in obesity
38. The endocannabinoid system as a target for obesity treatment
39. Intestinal lipase inhibitors
40. Sibutramine
41. Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat
42. 1α,25(OH)2D3 attenuates IL-6 and IL-1β-mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF-κB signaling pathways
43. Medication use for the treatment of diabetes in obese individuals
44. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials
45. Effect of CPAP on arterial stiffness in severely obese patients with obstructive sleep apnoea
46. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes
47. Correction to: Cardiac Autonomic Neuropathy in Obesity, Metabolic Syndrome and Prediabetes: A Narrative Review
48. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes
49. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation
50. THERAPEUTICS: Glucagon-like peptide-1 analogues for type 2 diabetes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.